L M Havekes

Author PubWeight™ 172.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999 2.75
2 Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease. Nat Genet 1994 2.65
3 Conjugation deficient E. coli K12 F- mutants with heptose-less lipopolysaccharide. Mol Gen Genet 1976 2.22
4 Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med 1994 2.11
5 Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res 2001 1.91
6 Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. Arterioscler Thromb Vasc Biol 2000 1.89
7 Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 2004 1.79
8 No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005 1.70
9 Association between apolipoprotein E epsilon4 and the rate of cognitive decline in community-dwelling elderly individuals with and without dementia. Arch Neurol 1998 1.67
10 Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1994 1.56
11 Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res 2001 1.43
12 Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem 1993 1.41
13 Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis 1996 1.40
14 Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis 1999 1.33
15 Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene. Biochem Biophys Res Commun 1988 1.31
16 Apolipoprotein e4 allele and cognitive decline in elderly men. BMJ 1994 1.31
17 Protection from obesity in mice lacking the VLDL receptor. Arterioscler Thromb Vasc Biol 2001 1.28
18 Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis 1994 1.28
19 In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes 2001 1.25
20 Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein C1. J Clin Invest 1998 1.23
21 Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes. J Clin Invest 1997 1.20
22 Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol 1996 1.20
23 Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 1993 1.19
24 Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death. Cell Death Differ 2006 1.15
25 A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987 1.15
26 Characterization of an Escherichia coli K-12 F-Con-mutant. J Bacteriol 1976 1.13
27 Protection from obesity and insulin resistance in mice overexpressing human apolipoprotein C1. Diabetes 2001 1.10
28 Intracerebroventricular administration of melanotan II increases insulin sensitivity of glucose disposal in mice. Diabetologia 2005 1.07
29 Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels. Hum Mutat 1994 1.07
30 Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J Biol Chem 1999 1.06
31 Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ 1995 1.06
32 Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis 1999 1.04
33 Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. Atherosclerosis 1995 1.03
34 The mouse low density lipoprotein receptor gene: cDNA sequence and exon-intron structure. Biochem Biophys Res Commun 1993 1.03
35 Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J Biol Chem 2001 1.01
36 Stimulation of the LDL receptor activity in the human hepatoma cell line Hep G2 by high-density serum fractions. Biochim Biophys Acta 1986 1.01
37 Macrophage low-density lipoprotein receptor-related protein deficiency enhances atherosclerosis in ApoE/LDLR double knockout mice. Arterioscler Thromb Vasc Biol 2006 1.01
38 Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun 1992 1.01
39 Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2000 1.01
40 Serum apolipoprotein E level is not increased in Alzheimer's disease: the Rotterdam study. Neurosci Lett 1998 1.01
41 Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice. Arterioscler Thromb Vasc Biol 2001 1.01
42 In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest 1996 1.00
43 The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem Pharmacol 2010 1.00
44 Epitopes of apolipoprotein B-100 and B-48 in both liver and intestine. Expression and evidence for local synthesis in recessive abetalipoproteinemia. J Clin Invest 1986 0.99
45 Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991 0.99
46 Apolipoprotein E genotype, atherosclerosis, and cognitive decline: the Rotterdam Study. J Neural Transm Suppl 1998 0.99
47 The apolipoprotein E epsilon 2 allele is associated with an increased risk of early-onset Alzheimer's disease and a reduced survival. Ann Neurol 1995 0.98
48 Sustained activation of the mammalian target of rapamycin nutrient sensing pathway is associated with hepatic insulin resistance, but not with steatosis, in mice. Diabetologia 2006 0.98
49 Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis 1998 0.97
50 Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J Hepatol 2001 0.96
51 White adipose tissue: getting nervous. J Neuroendocrinol 2003 0.96
52 Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem 2000 0.95
53 LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice. J Lipid Res 2000 0.95
54 Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem J 1997 0.94
55 The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005 0.94
56 Effect of human scavenger receptor class A overexpression in bone marrow-derived cells on lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knockout mice. J Lipid Res 2000 0.94
57 Living up to a name: the role of the VLDL receptor in lipid metabolism. Curr Opin Lipidol 2001 0.94
58 Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res 1997 0.94
59 Lipoprotein lipase stimulates the binding and uptake of moderately oxidized low-density lipoprotein by J774 macrophages. Biochem J 1996 0.93
60 Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol 1996 0.93
61 Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation 2001 0.93
62 Accelerated atherosclerosis by placement of a perivascular cuff and a cholesterol-rich diet in ApoE*3Leiden transgenic mice. Circ Res 2000 0.92
63 Regulation of low density lipoprotein receptor activity in primary cultures of human hepatocytes by serum lipoproteins. Hepatology 1987 0.92
64 The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J 1990 0.92
65 Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. J Neuroendocrinol 2008 0.92
66 ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb 1994 0.91
67 The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia. Atherosclerosis 1996 0.91
68 The mouse apolipoprotein C1 gene: structure and expression. Genomics 1993 0.91
69 Gut-brain axis: regulation of glucose metabolism. J Neuroendocrinol 2006 0.91
70 Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4. Alzheimer Dis Assoc Disord 1998 0.91
71 Mutations in the low density lipoprotein receptor gene of familial hypercholesterolemic patients detected by denaturing gradient gel electrophoresis and direct sequencing. J Lipid Res 1995 0.90
72 Evolutionary conservation of the mouse apolipoprotein e-c1-c2 gene cluster: structure and genetic variability in inbred mice. Genomics 1993 0.90
73 Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. Br J Pharmacol 2014 0.90
74 ApoE polymorphism accounts for only part of the genetic variation in quantitative ApoE levels. Genet Epidemiol 2000 0.90
75 Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis 2000 0.89
76 Apolipoprotein E protects against neuropathology induced by a high-fat diet and maintains the integrity of the blood-brain barrier during aging. Lab Invest 2001 0.89
77 Reversal of hyperlipidaemia in apolipoprotein C1 transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem J 1999 0.88
78 Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2001 0.87
79 Structure and expression of the mouse apolipoprotein C2 gene. Genomics 1993 0.87
80 Cafestol increases serum cholesterol levels in apolipoprotein E*3-Leiden transgenic mice by suppression of bile acid synthesis. Arterioscler Thromb Vasc Biol 2000 0.87
81 Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem 1989 0.86
82 The binding of human lipoprotein lipase treated VLDL by the human hepatoma cell line HepG2. Biochim Biophys Acta 1991 0.86
83 Apolipoprotein E and carotid artery atherosclerosis: the Rotterdam study. Stroke 2001 0.86
84 In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 --> Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. J Biol Chem 1996 0.86
85 The amino-terminal 1-185 domain of apoE promotes the clearance of lipoprotein remnants in vivo. The carboxy-terminal domain is required for induction of hyperlipidemia in normal and apoE-deficient mice. Biochemistry 2001 0.86
86 Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. Diabetologia 2006 0.86
87 Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest 1998 0.86
88 Reduced very-low-density lipoprotein fractional catabolic rate in apolipoprotein C1-deficient mice. Biochem J 1997 0.86
89 Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance. J Lipid Res 1990 0.86
90 Characterization of atherosclerotic lesions in apo E3-leiden transgenic mice. Atherosclerosis 1998 0.85
91 Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. Biochem J 1995 0.85
92 Altered lipid metabolism in apolipoprotein E-deficient mice does not affect cholesterol balance across the liver. Hepatology 1996 0.85
93 Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1997 0.85
94 Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 1996 0.85
95 Severe hyperlipidemia in apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism. Arterioscler Thromb Vasc Biol 1999 0.85
96 Inefficient degradation of triglyceride-rich lipoprotein by HepG2 cells is due to a retarded transport to the lysosomal compartment. J Biol Chem 1993 0.85
97 Transgenic mouse models to study the role of the macrophage scavenger receptor class A in atherosclerosis. Int J Tissue React 2000 0.84
98 Effective generation of very low density lipoprotein receptor transgenic mice by overlapping genomic DNA fragments: high testis expression and disturbed spermatogenesis. Transgenic Res 2001 0.84
99 Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models. Curr Atheroscler Rep 1999 0.84
100 The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. Br J Pharmacol 2009 0.84
101 Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis 1991 0.84
102 APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. Diabetes Obes Metab 2014 0.84
103 Dynamics of insulin signalling in liver during hyperinsulinemic euglycaemic clamp conditions in vivo and the effects of high-fat feeding in male mice. Arch Physiol Biochem 2007 0.84
104 The T705I mutation of the low density lipoprotein receptor gene (FH Paris-9) does not cause familial hypercholesterolemia. Hum Genet 1997 0.83
105 High fat diet induced hepatic insulin resistance is not related to changes in hypothalamic mRNA expression of NPY, AgRP, POMC and CART in mice. Peptides 2005 0.83
106 Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990 0.83
107 Macrophage specific overexpression of the human macrophage scavenger receptor in transgenic mice, using a 180-kb yeast artificial chromosome, leads to enhanced foam cell formation of isolated peritoneal macrophages. Atherosclerosis 1999 0.83
108 The effect of apolipoprotein(a)-, apolipoprotein E-, and apolipoprotein A4- polymorphisms on quantitative lipoprotein(a) concentrations. Twin Res 2000 0.83
109 Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice. Int J Tissue React 2000 0.83
110 Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia. Atherosclerosis 1996 0.83
111 Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4. Biochem Biophys Res Commun 1989 0.82
112 Mutational and genetic origin of LDL receptor gene mutations detected in both Belgian and Dutch familial hypercholesterolemics. Hum Genet 1997 0.82
113 Gender-related association between the -93T-->G/D9N haplotype of the lipoprotein lipase gene and elevated lipid levels in familial combined hyperlipidemia. Atherosclerosis 1998 0.82
114 Absence of mutations in the promoter region of the low density lipoprotein receptor gene in a large number of familial hypercholesterolaemia patients as revealed by denaturing gradient gel electrophoresis. Hum Genet 1992 0.81
115 Identification of a double mutation in the low-density lipoprotein receptor gene causing familial hypercholesterolemia. Clin Genet 1996 0.81
116 Hematopoietic α7 nicotinic acetylcholine receptor deficiency increases inflammation and platelet activation status, but does not aggravate atherosclerosis. J Thromb Haemost 2014 0.81
117 Effect of the APOE-491A/T promoter polymorphism on apolipoprotein E levels and risk of Alzheimer disease: The Rotterdam Study. Am J Med Genet 2002 0.81
118 Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E. Biochem J 2000 0.81
119 Rearrangements in the LDL receptor gene in Dutch familial hypercholesterolemic patients and the presence of a common 4 kb deletion. Atherosclerosis 1990 0.81
120 Analysis of the structure and function relationship of the human apolipoprotein E in vivo, using adenovirus-mediated gene transfer. FASEB J 2001 0.81
121 Lipid profiles reflecting high and low risk for coronary heart disease: contribution of apolipoprotein E polymorphism and lifestyle. Atherosclerosis 1998 0.81
122 Oxidized VLDL induces less triglyceride accumulation in J774 macrophages than native VLDL due to an impaired extracellular lipolysis. Arterioscler Thromb Vasc Biol 2000 0.81
123 Serum lipoproteins of healthy persons fed a low-fat diet or a polyunsaturated fat diet for three months. A comparison of two cholesterol-lowering diets. Atherosclerosis 1982 0.80
124 Identification of differentially regulated genes in mildly hyperlipidemic ApoE3-Leiden mice by use of serial analysis of gene expression. Arterioscler Thromb Vasc Biol 2001 0.80
125 Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor. J Biol Chem 2001 0.80
126 Inhibition of accelerated atherosclerosis in vein grafts by placement of external stent in apoE*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol 2002 0.80
127 Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Arterioscler Thromb 1991 0.80
128 An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins. J Biol Chem 1999 0.80
129 Binding of beta-VLDL to heparan sulfate proteoglycans requires lipoprotein lipase, whereas ApoE only modulates binding affinity. Arterioscler Thromb Vasc Biol 1999 0.80
130 Not the mature 56 kDa lipoprotein lipase protein but a 37 kDa protein co-purifying with the lipase mediates the binding of low density lipoproteins to J774 macrophages. Biochem J 1998 0.80
131 Physical activity modulates the effect of a lipoprotein lipase mutation (D9N) on plasma lipids and lipoproteins. Clin Genet 1999 0.79
132 Familial dysbetalipoproteinemic subjects with the E3/E2 phenotype exhibit an E2 isoform with only one cysteine residue. Clin Genet 1987 0.79
133 Lipoprotein profiles in a family with two mutants of apolipoprotein E: possible association with hypertriglyceridaemia but not with dysbetalipoproteinaemia. Clin Sci (Lond) 1994 0.79
134 Lipoprotein profile of a Greenland Inuit population. Influence of anthropometric variables, Apo E and A4 polymorphism, and lifestyle. Arterioscler Thromb 1992 0.79
135 Reversal of hypercholesterolemia in apolipoprotein E2 and apolipoprotein E3-Leiden transgenic mice by adenovirus-mediated gene transfer of the VLDL receptor. Arterioscler Thromb Vasc Biol 1998 0.79
136 Apolipoprotein E phenotype is not related to late-life depression in a population-based sample. Soc Psychiatry Psychiatr Epidemiol 1998 0.79
137 Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma. J Lipid Res 1993 0.79
138 Sex-specific effects of naturally occurring variants in the dopamine receptor D2 locus on insulin secretion and type 2 diabetes susceptibility. Diabet Med 2014 0.79
139 Mice expressing only the mutant APOE3Leiden gene show impaired VLDL secretion. Arterioscler Thromb Vasc Biol 2001 0.79
140 Functionally inactive apolipoprotein E3 in a type III hyperlipoproteinaemic patient. Eur J Clin Invest 1984 0.79
141 Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146-->Gln) are inefficiently converted to cholesterol-rich lipoproteins. Atherosclerosis 1994 0.78
142 Hyperlipidemia of ApoE2(Arg(158)-Cys) and ApoE3-Leiden transgenic mice is modulated predominantly by LDL receptor expression. Arterioscler Thromb Vasc Biol 1999 0.78
143 Molecular genetic testing for familial hypercholesterolemia: spectrum of LDL receptor gene mutations in The Netherlands. Clin Genet 2000 0.78
144 Effect of apolipoprotein E variants on lipolysis of very low density lipoproteins by heparan sulphate proteoglycan-bound lipoprotein lipase. Atherosclerosis 1998 0.78
145 Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers. J Clin Invest 1994 0.78
146 Lipolysis of very low density lipoproteins by heparan sulfate proteoglycan-bound lipoprotein lipase. J Lipid Res 1997 0.78
147 Regulation of cholesterol metabolism in the liver in vivo and in vitro. Biochem Soc Trans 1987 0.78
148 Effects of high fat diet on the Basal activity of the hypothalamus-pituitary-adrenal axis in mice: a systematic review. Horm Metab Res 2011 0.78
149 The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis 2000 0.78
150 Apolipoprotein A-IV polymorphism and its effect on plasma lipid and apolipoprotein concentrations. J Lipid Res 1988 0.78
151 Characterisation of the LDL receptor in Epstein-Barr virus transformed lymphocytes. Biochim Biophys Acta 1990 0.77
152 Plasma lipoproteins in familial dysbetalipoproteinemia associated with apolipoproteins E2(Arg158-->Cys), E3-Leiden, and E2(Lys146-->Gln), and effects of treatment with simvastatin. Arterioscler Thromb 1994 0.77
153 Efficient targeting of adenoviral vectors to integrin positive vascular cells utilizing a CAR-cyclic RGD linker protein. Biochem Biophys Res Commun 2005 0.77
154 A novel V415A mutation in exon 9 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. Clin Genet 1997 0.77
155 In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J Lipid Res 1999 0.77
156 Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. Hum Mol Genet 1995 0.77
157 Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia. Arterioscler Thromb 1994 0.77
158 Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs. Arzneimittelforschung 1998 0.77
159 Association of EGF and LDL receptors with the cytoskeleton of cultured keratinocytes. Cell Biol Int Rep 1990 0.77
160 Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipidol 1996 0.77
161 Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice. J Hepatol 2000 0.77
162 Dietary vegetable oil and wood derived plant stanol esters reduce atherosclerotic lesion size and severity in apoE*3-Leiden transgenic mice. Atherosclerosis 2001 0.77
163 Parental history of myocardial infarction: lipid traits, gene polymorphisms and lifestyle. Atherosclerosis 2001 0.77
164 The apolipoprotein C2-linked (Acl) gene: a new gene within the mouse apolipoprotein e-c1-c2 gene cluster. Genomics 1994 0.77
165 Effects of dietary fish oil on serum lipids and VLDL kinetics in hyperlipidemic apolipoprotein E*3-Leiden transgenic mice. J Lipid Res 1998 0.77
166 The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome. Eur J Clin Nutr 2010 0.76
167 Use of transgenic mice to study the role of apolipoprotein E in lipid metabolism and atherosclerosis. Int J Tissue React 2000 0.76
168 Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998 0.76
169 Rare apolipoprotein E variant cosegregating with a unique APOE-C1-C2 haplotype in a normolipidemic family. Hum Hered 1988 0.76
170 Serum lipoproteins in cholesterol-fed pigs after partial ileal bypass. Lab Anim 1985 0.76
171 Apolipoprotein E2 (Lys146-->Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides. Arterioscler Thromb Vasc Biol 2000 0.76
172 An acceptor splice site mutation in intron 16 of the low density lipoprotein receptor gene leads to an elongated, internalization defective receptor. Atherosclerosis 1993 0.76
173 Uptake by J774 macrophages of very-low-density lipoproteins isolated from apoE-deficient mice is mediated by a distinct receptor and stimulated by lipoprotein lipase. Arterioscler Thromb Vasc Biol 1997 0.76
174 Apolipoprotein epsilon 4 and coronary artery disease. Lancet 1992 0.75
175 Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia. Heart 2002 0.75
176 Apolipoprotein E phenotype and blood pressure. Lancet 1994 0.75
177 Fibrinogen genes and peripheral arterial disease. Lancet 1992 0.75
178 An additional MspI RFLP at the human hepatic lipase (HL) gene locus. Nucleic Acids Res 1990 0.75
179 Low-density lipoproteins are degraded in HepG2 cells with low efficiency. Biochem J 1993 0.75
180 The insulin sensitizing effect of topiramate involves KATP channel activation in the central nervous system. Br J Pharmacol 2013 0.75
181 Effect of macrophage-derived mouse ApoE, human ApoE3-Leiden, and human ApoE2 (Arg158-->Cys) on cholesterol levels and atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2000 0.75
182 Treatment of E2E2 homozygous familial dysbetalipoproteinemic subjects with gemfibrozil does not enhance the binding of their d < 1.019 lipoprotein fraction to the low-density lipoprotein receptor. Metabolism 1993 0.75
183 Identification of a splice-site mutation in the low density lipoprotein receptor gene by denaturing gradient gel electrophoresis. Hum Genet 1993 0.75
184 The effect of the apolipoprotein E phenotype on plasma lipids is not influenced by environmental variability: results of a Dutch twin study. Hum Genet 1993 0.75
185 The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. J Intern Med 2002 0.75
186 Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1. Diabetologia 2001 0.75
187 Effects of oral contraceptives on lipid metabolism. Am J Obstet Gynecol 1990 0.75
188 Regulation of low-density lipoprotein receptor expression during keratinocyte differentiation. J Invest Dermatol 1991 0.75
189 Variability in cholesterol content in serum and aortic tissue in apolipoprotein E-deficient mice is comparable in inbred (129/Sv) and outbred (mixed 129/Sv and C57BL/6) mice. Atherosclerosis 1995 0.75
190 Elevated levels of chylomicron- and VLDL-remnants leads to atherosclerosis in apoE transgenic mice. Z Gastroenterol 1996 0.75
191 Identification of three new mutations of the low density lipoprotein receptor gene in Dutch familial hypercholesterolemic patients. Hum Mutat 1998 0.75
192 Plasma plasminogen activator inhibitor-1 level is not regulated by the hepatic low-density lipoprotein receptor-related protein. J Thromb Haemost 2007 0.75
193 Immunological discrimination between the human apolipoprotein E2(Arg158----Cys) and E3 isoforms. J Lipid Res 1992 0.75
194 The effect of dietary linoleic acid and pectin on lipoprotein and apolipoprotein A1 concentrations in rhesus monkeys. Ann Nutr Metab 1984 0.75
195 Detection of allele-specific transcripts by the polymerase chain reaction (AST-PCR). Biochem Biophys Res Commun 1991 0.75
196 Apolipoprotein E genotype and concomitant clinical features in early-onset Alzheimer's disease. J Neurol 1996 0.75
197 The 13th annual meeting of the European Lipoprotein Club. Arterioscler Thromb 1991 0.75
198 Characterization of three human apolipoprotein E isoforms (E2, E3 and E4) expressed in Escherichia coli. Eur J Clin Chem Clin Biochem 1997 0.75
199 Effects of fenofibrate on hyperlipidemia and postprandial triglyceride metabolism in human apolipoprotein C1 transgenic mice. Atherosclerosis 1998 0.75
200 Familial dysbetalipoproteinemia: a genetically heterogenous disease caused by mutations of the ligand apolipoprotein E. J Invest Dermatol 1992 0.75
201 A novel mutation M-21V in exon 1 of the low density lipoprotein receptor gene causing familial hypercholesterolemia. Clin Genet 1997 0.75